Copyright
©The Author(s) 2020.
World J Gastrointest Pathophysiol. Apr 12, 2020; 11(2): 32-42
Published online Apr 12, 2020. doi: 10.4291/wjgp.v11.i2.32
Published online Apr 12, 2020. doi: 10.4291/wjgp.v11.i2.32
Outcome (cumulative) | Post-switch review (baseline), n (%) | As of 3y follow-up1, n (%) | As of 5y follow-up1, n = (%) | |||
Alternative 5-ASA2 | Resumed alsalazide | Alternative 5-ASA2 | Resumed balsalazide | Alternative 5-ASA2 | Resumed balsalazide | |
Escalated to immunomodulator | 14 (73.7) | 5 (41.7) | 16 (84.2) | 5 (41.7) | 16 (84.2) | 5 (41.7) |
Escalated to biologic | 0 (0) | 0 (0) | 3 (15.8) | 0 (0) | 6 (31.6) | 2 (16.7) |
Hospitalised for flare3 | 0 (0) | 0 (0) | 3 (15.8) | 0 (0) | 7 (36.8)a | 0 (0)a |
Colectomy | 0 (0) | 0 (0) | 1 (5.3) | 0 (0) | 1 (5.3) | 0 (0) |
All-cause mortality4 | 0 (0) | 0 (0) | 2 (10.5) | 0 (0) | 2 (10.5) | 0 (0) |
- Citation: van Langenberg DR, Cheng RKY, Garg M. Outcomes of a drug shortage requiring switching in patients with ulcerative colitis. World J Gastrointest Pathophysiol 2020; 11(2): 32-42
- URL: https://www.wjgnet.com/2150-5330/full/v11/i2/32.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v11.i2.32